New: NCI-funded clinical trial search
Mednet Logo
CommunityRheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

How do you manage a possible autoimmune sialadenitis arising from checkpoint inhibitor therapy?

1 Answers

Mednet MemberInvited Expert
Rheumatology · Ohio State University

This is a great question and a common clinical scenario in patients receiving immune checkpoint inhibitors. In my experience, severe sicca symptoms from immunotherapy are often not classic primary Sjögren's syndrome, despite some overlapping features. Rather, this appears to be an acute T-cell-media...

How would you treat SLE (inflammatory arthritis, +ANA/dsDNA/SSA) overlap with RA (CCP high titer) in a young female of childbearing age with low TPMT?

1 Answers

Mednet MemberInvited Expert
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

Whenever I have a patient with more than one systemic autoimmune disease, I often wonder which genotype/endotype is driving which manifestation. In this case... is it truly RA-driven inflammatory arthritis, or is it SLE arthritis? Depending upon the cohort, around 25% of SLE patients are anti-CCP po...

How do you approach a patient with GCA who has an allergic reaction to a biosimilar of tocilizumab but did well previously on originator tocilizumab?

1
1 Answers

Mednet Member
Rheumatology · Virginia Mason Franciscan Health Rheumatology Fellowship

I wonder whether they may have had a reaction to one of the inactive ingredients in the biosimilar! I would try to switch back to the originator tocilizumab. If unsuccessful even with an appeal, could also consider trying the other biosimilar available in the market, although I would prefer to use s...

About Mednet

A community where doctors find answers to medicine's toughest questions.

  • Verified, credentialed physicians
  • 45,000+ members across 24 specialties
  • Free CME and MOC credit

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...

In light of promising results of hydroxychloroquine in COVID-19, should we consider using it prophylactically in cancer patients, especially if immunocompromised?

2
1 Answers

Mednet MemberInvited Expert
Rheumatology · MD Anderson Cancer Center

At this time, as there is no good evidence available, I would not recommend the use of hydroxycholoroquine prophylactically in cancer patients. It is unclear whether it would prevent contagion, probably not, and we still don't know if it will have any effect on the course of COVID-19. We expect ther...

When do you prefer bariatric surgery such as sleeve gastrectomy or gastric bypass over an initial trial of a GLP-1 receptor agonist in patients with severe obesity and painful knee or hip osteoarthritis?

1
2 Answers

Mednet Member
Rheumatology · Sorbonne Université

I believe that this type of decision should be made by obesity specialists and not by rheumatologists. However, we can anticipate that the patient's choice is paramount: some prefer radical options such as surgery, while others cannot bear to hear about it. The decision should only be made through d...

How often do you draw screening ANAs for discoid lupus?

1
4 Answers

Mednet MemberInvited Expert
Rheumatology · Harvard Medical School

Because a positive ANA is associated with an increased risk of progression to SLE in patients with discoid lupus, I routinely check an ANA at the initial visit in virtually all patients. If negative, I repeat it only if new symptoms concerning systemic involvement arise (e.g., joint pain, cytopenias...

Where in the sequence of biologics would you consider guselkumab for patients with active psoriatic arthritis despite standard DMARD therapy?

3 Answers

Mednet Member
Rheumatology · Mayo Clinic Jacksonville

This is an extremely important question and one that is likely to change as new data becomes available. It is important to remember that psoriatic arthritis (PsA) is a complex and heterogeneous disease and a single approach does not work for every patient. Based on the ACR/NPF 2019 PsA treatment gui...

What strategies have you found most helpful to improve adherence to hydroxychloroquine among patients with lupus?

1
3 Answers

Mednet MemberInvited Expert
Rheumatology · University of Alabama at Birmingham

In my practice, three approaches have been most useful: Make adherence measurable. I routinely check whole-blood hydroxychloroquine levels and review the trend with patients in a nonjudgmental way. This creates accountability and turns an otherwise “invisible” treatment into something concrete that ...

What is your experience with using anabolic therapy for treatment of osteoporosis in patients with EtOH cirrhosis and is one agent preferred over another (PTH analogue vs Evenity)?

1
2 Answers

Mednet MemberInvited Expert
Endocrinology · Boston University School of Medicine

The approach that has been recommended may be reasonable. It is important to recognize that a bone density score consistent with osteoporosis does not necessarily mean that the patient has osteoporosis i.e. loss of mineral and matrix. Osteomalacia, a mineralization defect of the collagen elastin mat...